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Abstract
Background: The dopamine (DAT), noradrenalin (NET) and serotonin (SERT) transporters are molecular targets for
different classes of psychotropic drugs. Cocaine and the SSRI (S)-citalopram block neurotransmitter reuptake
competitively, but while cocaine is a non-selective reuptake inhibitor, (S)-citalopram is a selective SERT inhibitor.
Findings: Here we present comparisons of the binding sites and the electrostatic potential surfaces (EPS) of DAT,
NET and SERT homology models based on two different LeuTAa templates; with a substrate (leucine) in an
occluded conformation (PDB id 2a65), and with an inhibitor (tryptophan) in an open-to-out conformation (PDB id
3f3a). In the occluded homology models, two conserved aromatic amino acids (tyrosine and phenylalanine) formed
a gate between the putative binding pockets, and this contact was interrupted in the open to out conformation.
The EPS of DAT and NET were generally negative in the vestibular area, whereas the EPS of the vestibular area of
SERT was more neutral.
Conclusions: The findings presented here contribute as an update on the structure of the binding sites of DAT,
NET and SERT. The updated models, which have larger ligand binding site areas than models based on other
templates, may serve as improved tools for virtual ligand screening.
Introduction
There are three main dopaminergic pathways in the
brain, the mesolimbic/mesocortical pathway involved in
emotion- and drug-induced reward systems, the nigros-
triatal pathway involved in motor control, and the
tuberohypophyseal neurons involved in regulation of
secretions from pituitary gland. The reward system is
linked to drug abuse, and it is activated when a person
receives positive reinforcement for certain behaviors,
which can be artificial rewards (addictive drugs) or nat-
ural rewards (sex or food). When cocaine binds to DAT,
a “reward” associated with an elevated dopamine con-
centration in the synapse in the Nucleus Accumbens
occurs [1]. Individuals with the hypodopaminergic trait
involving an impairment of the reward cascade ("Brain
Reward Cascade Model”)t e r m e d“Reward Deficiency
syndrome” (RDS), which may be due to several genes,
and also due to environmental stimuli, have higher risk
for substance abuse, impulsive behavior, eating bingeing,
pathological gambling, ADHD and sex addiction etc.
[2,3].
Cocaine has similar binding affinities for DAT and the
noradrenalin (NET) and serotonin (SERT) transporters.
In addition to stimulant action, NET and SERT are
molecular targets for antidepressants (selective serotonin
reuptake inhibitors (SSRIs), selective noradrenaline
reuptake inhibitors (NERI), serotonin-noradrenalin reup-
take inhibitors (SNRI), and tricyclic antidepressants
(TCA)). Binding studies have demonstrated that SSRIs
are from 300 to 3,500 times more selective for SERT
over NET, and generally have low affinities for DAT [4].
DAT, NET and SERT belong to the large neurotrans-
mitter: sodium symporter (NSS) family of transporters
[5], and they regulate monoamine concentrations at
neuronal synapses by carrying monoamines across neu-
ronal membranes into presynaptic nerve cells, using an
inwardly directed sodium gradient as an energy source.
Cocaine elevates the concentration of all three neuro-
transmitters at synapses, while SSRIs and NERIs elevate
the concentration of serotonin and noradrenaline,
respectively. Both serotonergic and noradrenergic neu-
rons are localized in the pons and medulla (raphe
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any medium, provided the original work is properly cited.nuclei), and their axons project to brain regions such as
the limbic system, the cerebral cortex and
hypothalamus.
Structural information about DAT, SERT and NET
and their drug interactions is important for understand-
ing their molecular mechanisms of action, and provide
useful tools for new drug discovery. Elucidating differ-
ences in binding site conformations of occluded and
open-outward neurotransmitter transporter models, and
investigating differences in the electrostatic potential
surfaces of the three transporters, may give insight into
binding modes of drugs in different conformations and
to the different transporters. No X-ray crystal structures
of mammalian human DAT, SERT or NET have been
reported, but several Aquifex aeolicus LeuTAa crystal
structures have been published [6-8]. LeuTAa is a bac-
terial homologue of DAT, SERT and NET that is
regarded as suitable template for molecular models of
these transporters. The sequence identity between Leu-
TAa and DAT, NET and SERT is ~20% [9].
Methods
In present study, we have used the crystal structure of
LeuTAa, complexed with an inhibitor (tryptophan) in an
open-to-out conformation [6] (PDB id 3f3a) as a tem-
plate for molecular modeling of DAT, SERT and NET.
We have compared the binding site conformations of
the models with the binding site conformations of our
previous DAT, SERT and NET models [10] that were
based on the crystal structure of LeuTAa,c o m p l e x e d
with a substrate (leucine) in an occluded conformation
[7] (PDB id 2a65). Molecular models of DAT, NET and
SERT were constructed using the ICM version 3.6 [11].
The modeling procedure of DAT, NET and SERT based
on LeuTAa in the occluded conformation [7] has pre-
viously been described in [10]. A comprehensive amino
acid sequence alignment [9] of all known prokaryotic
and eukaryotic neurotransmitter: sodium symporter
(NSS) proteins including DAT, NET and SERT, was
used as input alignment. In the ICM homology model-
ing module, the model is constructed from a few core
sections defined by the average of Ca atom positions in
the conserved regions. Loops are searched for within
several thousand high quality three dimensional (3D)
protein structures by matching them with regard to
sequence similarity and steric interactions with the sur-
roundings of the model. The best fitting loop is selected
by calculating the maps around the loops and scoring
them based on their relative energies.
The models were refined by globally optimizing side-
chain positions and annealing of the backbones using
the RefineModel macro of ICM. This macro included
(1) a Monte Carlo simulation [12] of side chains, (2) five
steps of iterative annealing of the backbone structure,
Figure 1 Backbone Ca-traces of occluded DAT model [10](A)
and Open-to-out DAT model (B) viewed in the membrane
plane cytoplasm downwards. Binding sites as detected by ICM
PocketFinder are displayed in yellow (S1) and green (S2) (A); and in
yellow (B). Coloring of the C-alpha traces of the model is blue via
white to red from N-terminal to C-terminal.
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In step 1 of the RefineModel macro, a side-chain con-
formational analysis using the “MonteCarlo fast” option
of the ICM global optimization procedure for sampling
of the conformational space of a molecule, is performed
[12]. Iterative random movements, followed by local
energy minimizations, and by a complete energy calcula-
tion, were performed, and each iteration was accepted
or rejected based on energy and temperature criteria.
Step 2 performed an iterative annealing of the backbone
with provided tethers, which are harmonic restraints
pulling an atom in the model to a static point in space
represented by a corresponding atom in the template. A
second Monte Carlo side-chain sampling was performed
in step 3.
The ICM PocketFinder algorithm, which detects cav-
ities of sufficient size to bind ligands, [13] was used to
detect putative drug binding pockets in the DAT, NET
and SERT models. A tolerance level of 3 was used, thus
cavities with a volume greater than 3 Å
3 were consid-
ered. The reason for choosing a tolerance level of 3,
instead of the default tolerance level of 4.6, is that a lar-
ger area is detected as a binding pocket. The algorithm,
which uses a transformation of the Lennard-Jones
potential calculated from a three-dimensional protein
structure, does not require any knowledge about a
potential ligand molecule. Thus, the ICM PocketFinder
algorithm is based solely on protein structure [13]. The
detected putative drug binding pockets were compared
with detected putative drug binding pockets in DAT,
NET and SERT in occluded conformation [10].
Results and discussion
The occluded and open-outward DAT models, with
substrate binding pockets displayed, are shown in Figure
1. Two putative ligand binding pockets “S1” (substrate
binding site) and “S2” (vestibular binding site) were
detected in the occluded conformation, while in the
open-to-out conformation the binding sites were “fused”
and overlapping, yielding one large ligand binding
pocket. Amino acids reported by ICM PocketFinder to
contribute to the binding pockets of the open-to-out
DAT, NET and SERT models are shown in Table 1.
Two conserved aromatic amino acids (tyrosine and phe-
nylalanine) formed a gate between the putative binding
pockets in the occluded conformation, and the contact
between these two amino acids was interrupted in the
open to out conformation (Figure 2). Thus, when the
transporter opens towards the extracellular side, these
two amino acids part and the two binding sites merge
into one large ligand binding area. Hindering the extra-
cellular gate by separating the two amino acids with an
aromatic moiety may be a mechanism for transporter
inhibition. In a new and promising method for treating
drug addicts, RDS is targeted by amino-acid precursor-
enkephalinase therapy (NAAT), which in the long term
activates dopamine, thus reducing vulnerability to
relapse [2]. Interestingly, amino acids included in this
neuronutritient include tyrosine and phenylalanine [14].
While these amino acids are precursors for dopamine,
they could also, when administered in significant
amounts, be interacting with the “Tyrosine-Phenylala-
nine Gate”, thus temporarily blocking dopamine reup-
take and increasing dopamine concentration at the
synapse.
The stereochemical qualities of the models were
checked using the StructuralA n a l y s i sa n dV e r i f i c a t i o n
Server (SAVS) http://nihserver.mbi.ucla.edu/SAVS/. Pro-
grams run on SAVS, which examine the stereochemical
quality of a protein structure by analyzing its overall
and residue-by-residue geometry, were Procheck [15],
What_check [16], and Errat [17]. The overall quality fac-
tors of the DAT, NET and SERT models were 90.0, 93.7
and 87.6, respectively. The DAT model Ramachandran
plot revealed that 93.8% of the residues were in the
most favored regions, 5.9% were in additional allowed
regions, 0.3% were in generously allowed regions, and
0.0% were in disallowed regions. The Ramachandran
plot of NET reported 93.7% (most favored regions),
6.1% (additional allowed regions), 0.3% (generously
allowed regions), and 0.0% (disallowed regions), and the
Ramachandran plot of SERT reported 94.0% (most
favored regions), 6.0% (additional allowed regions), 0.0%
(generously allowed regions), and 0.0% (disallowed
Table 1 Amino acids reported by ICM PocketFinder to contribute to the binding pockets of open-to-out DAT, NET and
SERT
DAT NET SERT
TMH1 F76, A77, D79, L80 A81, W84, R85, Y88 F72, A73, D75, L76, A77, W80, R81, Y84 Y95, A96, D98, G100, W103, R104, Y107, I108
TMH3 V152, F155, Y156, I159 145, V148, Y151, Y152, I155, W158 A169, I172, A173, Y175, Y176, I179, W182
TMH6 F320, S321, G323, F326, V328 F317, S318, G320, F323, V325 F335, L336, L337, G338, F341, V343
EL4 V382, A383, K384, D385, G386, P387, L389, I390 A380, E382, G383, A384, L386, V387, F388 A398, K399, D400, A401, P403, L405, L406, F407
TMH8 S422, A423, G426 S419, S420, G423 S438, T439,
G442
TMH10 F472, D476, A480 G465, I466, L469, T470 E493, T497
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What_check.
The electrostatic potential surfaces (EPS) of the DAT,
NET and SERT models were calculated with the ICM
program, with a potential scale from -10 to +10 kcal
mol
-1.T h eE P So ft h eD A T ,N E Ta n dS E R Tm o d e l s
viewed from the extracellular side are shown in Figure
3. While the EPS of DAT and NET were generally nega-
tive in the vestibular area, the EPS of the vestibular area
of SERT was more neutral, with certain concentrated
negative areas. The entrance into the S1 binding area is
seen in the lower right area of each transporter. The S1
entrance of SERT was more clearly defined as a negative
area than those of DAT end NET. These differences in
electrostatics may partly explain the differences in drug
recognition of DAT, NET and SERT.
The ligand binding site areas of our previous DAT,
NET and SERT models [10] were tighter, possibly
resulting in a greater chance of sterical hindrance for
docked ligands. The updated models presented in this
short report, which have larger ligand binding site areas
than models based on other templates, may serve as
improved tools for virtual ligand screening.
Co-ordinates of the DAT, NET and SERT models are
available from the authors upon request.
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